Recommended Topic Related To:


"Nov. 6, 2012 -- The FDA has approved Pfizer's Xeljanz (tofacitinib), a first-of-its-kind treatment for rheumatoid arthritis.

Xeljanz is approved for use by patients not helped by methotrexate, the usual first treatment for RA. It's a "...


Myochrysine Patient Information including If I Miss a Dose

What happens if I miss a dose (Myochrysine)?

Doses are given on a weekly basis. You should receive the missed dose as soon as possible, but a double dose should not be injected to make up for a missed dose.

What happens if I overdose (Myochrysine)?

Seek emergency medical attention if an overdose is suspected.

Symptoms of an gold sodium thiomalate overdose include blood in the urine, painful urination, fever, sores or ulcers in the mouth, nausea, vomiting, diarrhea, rash, and itching. A gold sodium thiomalate overdose can result in death.

What should I avoid while using gold sodium thiomalate (Myochrysine)?

In rare cases, exposure to sunlight may cause areas of the skin to turn a bluish-gray color. To lessen this effect, minimize exposure to sunlight and wear a sunscreen and protective clothing when exposure to the sun is unavoidable.

What other drugs will affect gold sodium thiomalate (Myochrysine)?

Before using gold sodium thiomalate, tell your doctor and pharmacist about all prescription and over-the-counter medicines that you take, including vitamins, minerals, and herbal products, so that your treatment can be monitored for interactions.

Where can I get more information?

Your pharmacist has more information about gold sodium thiomalate written for health professionals that you may read.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 3.07. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.


Side Effects Centers

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get the latest treatment options